JXTGE to sell Irvine Scientific to FujiFilm3 Apr 2018
With the acquisition of Irvine Scientific, FujiFilm will have a full product line supporting customers supplying antibody drugs to assisted reproductive technologies and cell therapy.
JXTG Nippon Oil & Energy Corporation has agreed to sell Irvine Scientific Sales Company and IS Japan Co. to FUJIFILM Corporation (FujiFilm).
JXTG Energy acquired Irvine Scientific in 1987 and launched IS Japan in 1989; both companies have continuously expanded to become significant suppliers of cell culture media and products to the biopharmaceutical, cell therapy and medical markets in their respective regions. Although the business has experienced significant growth, life sciences and medical devices are not synergistic for JXTG Energy’s core business going forward.
JXTG Energy determined it would be best for the Irvine Scientific group to continue under ownership which is synergistic to Irvine Scientific products and services.
FujiFilm announced it would acquire the Irvine Scientific group and maximize their synergy in its significant and growing bio-medical businesses. FujiFilm expects increased demand and needs of biopharmaceutical products and regenerative medicine therapy is driving current rapid growth of the cell culture media market and estimates continued strong growth in the coming years.
Irvine Scientific is an innovator of cell culture media, to biopharmaceutical, assisted reproductive technology, and regenerative medicine customers. By applying its high capabilities in R&D and quality systems, coupled with long experience, Irvine Scientific has developed a strong presence serving customer needs. Irvine Scientific’s California, USA and Saitama, Japan cGMP facilities will be transferred and provide capacity to supply high-quality products in a timely manner worldwide.
FujiFilm is advancing growth strategies within healthcare space, investing in biopharmaceutical contract development/manufacturing, and regenerative medicine. Prior to this announcement, FujiFilm acquired the global leader in iPS cell technologies, Cellular Dynamics International (CDI) and has entered into cell culture media space with the acquisition of general reagents manufacturer, Wako Pure Chemical Industries (Wako Pure Chemical). With the acquisition of Irvine Scientific, FujiFilm will have a full product line supporting customers supplying antibody drugs to assisted reproductive technologies and cell therapy, and will also enable FujiFilm to strengthen its overseas business. FujiFilm announced it plans to further accelerate competitive media development and expand cell culture media business by applying chemical synthesis and design technologies acquired through its original business in photographic films and from Japan Tissue Engineering (“J-TEC”), as well as cell growth and manufacturing technologies from CDI and FUJIFILM Diosynth Biotechnologies.
In addition, FujiFilm plans on maximizing synergies outside of cell culture business, combining media technologies and products of Irvine Scientific with FujiFilm Group’s biomedical technologies and products. Specific synergies mentioned include (1) expansion of contract development/manufacturing of biomedicine (2) acceleration of R&D in regenerative medicine (3) expansion of research-purpose chemical reagents business.
The Irvine Scientific Group is excited about this change and anticipates continued acceleration of its cell culture media businesses under new ownership.
Specialist API CDMO acquired by GHO Capital
16 Mar 2019
Future plan is to extend Sterling’s international presence to meet increasing demand from customers worldwide.Read more
Bringing next generation single-use sensor technologies to the life science market
14 Mar 2019
Pall and Broadley-James’ combined expertise proves complementary in addressing critical customer pain points in modern bioprocessing.Read more
Third Sartorius Research Xchange Forum 2019 focuses on CAR-T cell therapy
13 Mar 2019
Event for experts from academia and industry, including talks, live demo sessions, and panel discussion.Read more
TraceLink submits an interoperable blockchain network solution for FDA DSCSA Pilot Project Program
12 Mar 2019
Trace Histories is a purpose-built distributed ledger solution for ensuring patient safety by 2023 DSCSA deadline.Read more
Overcoming lyophilization challenges at Interphex 2019
10 Mar 2019
Line of Sight approach to freeze-drying enables organizations to bring pharmaceutical products safely and quickly to market.Read more
Catalent invests over $27 million to commercialize Zydis Ultra
7 Mar 2019
Zydis Ultra allows a patented and innovative drug coating to be introduced during a product’s formulation, enabling the dosage of active ingredient to be up to four times higher than a conventional Zydis ODT.Read more
Novel systems for membrane chromatography
6 Mar 2019
Optimally run membrane chromatography processes will provide higher productivity, smaller-scale operations and increased robustness.Read more
Lilly to introduce lower-priced insulin
5 Mar 2019
Authorized generic version of Humalog will be available in US pharmacies at 50% lower list price.Read more
Biogen acquisition boosts its ophthalmology pipeline
4 Mar 2019
Nightstar Therapeutics has two potentially first-in-class mid- to late-stage clinical assets as well as preclinical programs.Read more
Uniqsis expands LED photoreactor range
3 Mar 2019
The availability of three new alternative switchable LED configurations provides chemists with the unique ability to optimally undertake almost any photochemistry reaction.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation